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HIV infected individuals showawide spectrum of changes caused by
systemic immunosuppression homing from the virus itself or therapies
used to improve this state. Uncontrolled replication of the virus causes
changes in lipid proﬁle, such as increased levels of triglycerides, low
density lipoprotein and decreased high density lipoprotein, to promote
a dyslipidemia condition [1].
Oxidative stress is also elevated in HIV+ patients due to excessive
production of free radicals that play a major role in oxidative
modiﬁcation in LDL particle [2]. HIV+ patients with low counts of T
CD4 cells show reduced plasma levels of anti-LDLm (LDLmodiﬁed), and
these low levels of antibodies are also associatedwith the lipodystrophy
syndrome [3]. Serum levels of OxLDL are higher in HIV+ patients on
antiretroviral therapy especially in patients with lipodystrophy syn-
drome compared with soronegative patients [4]. There are also other
types of disorders that are frequent in HIV infection, such as endothelial
dysfunction andmetabolic disorders including insulin resistance [5]. All
these factors increase the risk of HIV+ patients to accelerate the
progression of the atherosclerosis.
In this cross-section study,we included consecutive 69adult patients
of both genderwith sorological positive to HIV infection. In HIV-infected
individous were evaluated immune markers, HIV infection parameters
and autoimmune response to oxidized low density lipoprotein. Ethical
approvalwas obtained from the local institutional ethics committee and
written consent was obtained from all patients.
We evaluated several patient characteristics related to HIV infection,
including lypodistrophy, antiretroviral therapy, AIDS, time of treatment
with HAART, and AIDS-related diseases (e.g. hepatitis, tuberculosis,
Kaposi sarcomas, pneumonia, candidiase, and leucoplasia pilosa).
Anthropometric variables, including body mass index (BMI), gender,
age, smoking status and treatment with hypolipidaemic, antiretroviral
drugs and nadir CD4 T-cell count documented were recorded. The
presence of hypertension or diabetes was deﬁned according to standard
international criteria [6]. Lipodystrophy was deﬁned as the presence of
body fat changes that could be clearly recognized by the patient and
conﬁrmed by the doctor. Plasma viral load was measured with the
Cobass TaqMan HIV-1 assay (Roche, Basel, Switzerland) and CD4 T-cell
countwas determined by ﬂowcytometry (Beckman–Coulter). A sample
of fasting venous blood was obtained during the clinical examination.
Serum total cholesterol and triglyceride concentrations were mea-
sured by standard methods (Beckman–Coulter, Fullerton, CA, USA). HDL
cholesterol was analyzed using a homogeneous method (Beckman–
Coulter). LDL concentrations were calculated using the Friedewald
formula [7].
The cytokines pro-inﬂammatory and anti-inﬂammatory were eval-
uated by ELISA, according to the information provided by the
manufacturer (R&D Systems, Minneapolis, MS). To determine the Abs
to copper-oxidized LDL, we used an established assay as previously
described [8]. Brieﬂy, an aliquot of the plasma sample (3.5 L/ml) was
added onto microliter plates coated with 1 μg/ml human oxLDL (20 mM
Cu2+, 24 h), blocked with a 1% solution of gelatin and incubated
overnight with mouse plasma samples (50 μL; diluted 1:400). A
peroxidase-conjugated secondary goat anti-mouse IgG antibody
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Table 1
Demographic, clinical and biological characteristics of the subjects infected with HIV virus.
Patients (n) 69
Gender (males/females) 49/20
Age (years) 46±7.6
Cardiovascular disease risk factors
Diabetes N (%) 4 (6)
Hypertension N (%) 13 (18)
Dyslipidaemia N(%) 6 (9)
Smoking N (%) 13 (18)
Body mass index (kg/m2), mean values±SD 24.4±3.2
Lipid proﬁle
Total cholesterol (mg/dl), mean values±SD 181±46
LDL-C (mg/dl), mean values±SD 110±29
HDL-C(mg/dl), mean values±SD 44±12
Triglycerides (mg/dl), mean values±SD 171±112
TC/HDL-C, mean values±SD 4.1±2.9
Risk factors for HIV infection
Time of treatment with HAART (years) 9.6±3.5
AIDS-related disease (%) 15 (21)
Hepatitis C virus coinfection (%) 9 (13)
Lipodistrophy (%) 11 (16)
Antiretroviral therapy
NRTIs N(%) 64 (92)
Protease inhibitors N (%) 39 (56)
NNRTIs N (%) 25 (35)
Current CD+4 cell count (cells/μL) 520±266
Nadir CD4+ cell count (cells/μL) 209±157
Viral loadb40 copies/ml (%) 65 (94)
Inﬂammation and oxidation markers
IL-1β (pg/ml), median (IQR) 2.88 (2.48–4.53)
IL-6 (pg/ml), median (IQR) 5.36 (3.57–9.05)
IL-10 (pg/ml), median (IQR) 7.36 (6.81–10.81)
TNF-α (pg/ml), median (IQR) 2.46 (2.39–4.37)
Abs anti-OxLDL (IR), median (IQR) 0.25 (0.20–0.35)
Abbreviations: TC/HDL: total cholesterol/high density lipoprotein; HAART: highly active
antiretroviral therapy; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs:
nonnucleoside reverse transcriptase inhibitors; Abs anti-OxLDL: autoantibodies anti-
OxLDL; RI: reactivity index, IQR: interquartile range.
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(50 μL; diluted 1:400)wasused to detect anti-OxLDL. Theoptical density
was measured at 450 nm (Titertek Multiskan MCC/340P, model 2.20;
Labsystems). The procedure for the copper-oxidized LDL (7.5 μg/ml)
followed smaller modiﬁcations as described by Ketelhuth et al. [9].
The present studywas approved by institutional ethics committee of
Dental School of University of Sao Paulo, and informed consent was
obtained from each patient.
Results are expressed as means±SD or median values and inter-
quartile range. Categorical variables were expressed as number of
subjects and percent values. Variables with non-Gaussian distribution
were log-transformed for comparisons. Analyses of variance with
Tukey's post-test were used to examine comparisons between groups
of CD4 T-cell counts or in the case of the non-Gaussian distribution, the
Mann–Whitney U-test was used. Correlations between variables were
tested by Pearson test. Factors independently associated with anti-
OxLDL Abs were identiﬁed with multivariable linear regression. A P
value of b0.05 was considered signiﬁcant. Statistical analyses were
performed with SPSS 17.0.
Demographic characteristics of patients are presented in Table 1. In
the present study we have shown that hypertension and smoking are
major risk factors of cardiovascular disease. The time of therapy with
HAART is elevated to 9.6 years revealing great exposition of HIV
infection. The medications very prevalent in use were nucleoside
reverse transcriptase inhibitors with 92% and protease inhibitors with
56%. The viral load show nine patients presented values undetectable
and with mean of CD4 presented above to 500 cells count. Only four
patientes show viral load N40 copies/ml (Table 1).
The patients were separated by CD4 cell counts; b200 cells/μL (10
patients); 201–499 cells/μL (30 patients); ≥500 cells/μL (29 patients),
in accordance with the deﬁnitions of CDC [10].
However patients who had CD4 counts less than 200 (cells/μL), in
AIDS, have higher concentrations of anti-OxLDL Abs, differently
according to the stages of the disease (Fig. 1A). These same patients
also showed a rise to AIDS elevated concentrations of TNF-α, revealing
an inﬂammatory component associated with lower amounts of CD4
cells (Fig. 1B).
No differences in other cytokines between groups by CD4 cell counts
were observed.
We found that current CD4 cells and anti-OxLDL Abs exhibit an
inverse correlation (r=−0.26, P=0.02) as observed in Fig. 2A. This
correlationwasmaintained in relation to the levels of nadir CD4 cells hit
by study subjects (r=−0.34, P=0.004; Fig. 2B).
Multiple linear regression including autoantibodies anti-OxLDL as
dependent variable showed that nadir reached CD4+ and TNF-α
remained independently associated with anti-OxLDL (Table 2). When
patients had low nadir of CD4+ cells and had high TNF-α concentra-
tion, titers of anti-OxLDL Abs increased.
In conclusion, our results show that anti-oxLDL IgG Abs are elevated
in HIV-infected patients with CD4 cell count less. This phenomenon is
associated with increases levels of TNF-alfa and nadir of CD4 cell count.
The oxidation process in HIV infection promote modiﬁcation in LDL
particle in which new antigens are generated. This promotes lifting in
autoimmune response to epitopes of the oxLDL. One possible cause this
response may be the modulation in survival and memory of antigen
Fig.1. (A) Titers of the autoantibodies anti-OxLDL inHIV-infected patients according to the stages of infection by CD4 cell counts. (B) Serum concentrationTNF-alfa ofHIV-infectedpatients
in relationship to CD4 cell counts. RI: reactivity index. Comparisons between groups were made by using the ANOVA test with Tukey pos-test. TNF-alfa presented in log transformed.
Fig. 2. (A) Scatter plots showing inverse correlation (r=−0.26; P=0.02) between titers of autoantibodies (Abs) anti-OxLDL and CD4 cell counts in baseline study. (B) Scatter plots
showing inverse correlation (r=−0.36; P=0,004) were observed among titers of Abs anti-OxLDL and nadir CD4 cell counts. RI: reactivity index; all correlations were made by
Pearson correlation test.
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presenting cells by HIV virus, these cells are responsible for antibodies
production.
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Following prolonged endurance exercise (e.g. marathon running),
circulating levels of cardiac troponin are increased in more than 50% of
individuals [1]. Also after controlled laboratory-based exercise of shorter
duration plasma troponin concentration increases, but these data are
sparse [2,3]. Up to now, the underlying mechanism of troponin
appearance after strenuous exercise in humans is unknown. Many
theories have been posed, including exercise-induced increase in
cardiomyocyte membrane permeability or cardiomyocyte injury due
to ischemia reperfusion (IR) [1]. In this studywe aimed to investigate
whether IR-injury contributes to the rise in circulating troponin after
strenuous exercise in healthy volunteers. Remote ischemic precondition-
ing (RIPC) is a powerful strategy to limit IR-injury [4]. Therefore, in a
randomized controlled cross-over study inhealthy volunteers,we studied
the effect of RIPC on exercise-induced troponin I release. If IR-injury
contributes to the plasma appearance of troponin in this model, then
exercise-induced troponin release can be used as a model of myocardial
IR-injury in healthy volunteers.
The studywas approved by the local ethics committee. After informed
consent, twenty healthy volunteers (age 22±4 years, 10 males)
participated. Before randomization, all volunteers underwent a maximal
cycling test to determine maximum heart rate. Subsequently, in a
crossover design, all volunteers performed a submaximal exercise test
preceded by RIPC or a control intervention. The tests were separated by
two weeks and the order was randomized. After 30 min of supine rest,
subjects performedbicycle exercise at 80%of theirmaximumheart rate or
heart rate reserve (whatever resulted in the highest target heart rate) for
70 min, immediately followed by cycling at 95% of maximal heart rate
reserve until exhaustion or for a maximum of 15 min. The RIPC stimulus
was applied during the 30 min immediately before the exercise test. RIPC
consisted of three 5-min cycles of bilateral forearm ischemia, induced
Table 2
Multiple linear regression showing signiﬁcant associations between Abs anti-OxLDL
antibodies, biomarkers for HIV infection and inﬂammation.
Coefﬁcients t P 95% conﬁdence
interval
B SE Lower Upper
Constant 0.364 0.158 2.298 0.025 0.133 0.666
Age, per years 0.001 0.002 0.285 0.777 −0.003 0.004
Body mass index, kg/m2 −0.003 0.005 −0.702 0.485 −0.013 0.006
Time of medication,
per years
−0.005 0.004 −0.125 0.270 −0.013 0.004
Nadir CD4+, per cells/μL −0.066 0.031 −2.117 0.038 −0.125 −0.004
TNF-αa (pg/ml) 0.356 0.103 3.463 b0.001 0.150 0.561
In bold statistically signiﬁcant association (Pb0.05).
a Variables log transformed.
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